Pink SheetWith 10 novel applications with August user fee goal dates remaining under review, the US Food and Drug Administration could make some headway toward FDA Commissioner Martin Makary’s ambitious 2025 ap
ScripNot quite two years after raising $175m in series C cash , inhaled respiratory therapy-focused Avalyn Pharma revealed on July 22 that it has raised a $100m series D round that CEO Lyn Baranowski said
ScripInsmed has opened a new research center in Cambridge, UK, where its researchers are looking to generate a new class of drugs to treat genetic diseases based on ‘synthetic rescue.’ The opening of the s
Pink SheetThe US Food and Drug Administration’s approval decisions for novel agents will come from different divisions in the second half of 2025, compared to the first half, the Pink Sheet ’s US FDA Performan